US-based Mevion Medical Systems, a leading provider of small proton therapy systems for cancer treatment, has recently announced that it has signed a partnership agreement with Hermes Advanced Therapy Systems Corp. (HATS) in Taiwan and Southeast Asia (Including Malaysia, Thailand and Singapore) distributing MEVION S250i Proton Therapy System. 

Since 1977, Hermes-Epitek Corp. has been a trusted provider of high-tech equipment and services. Its subsidiary HATS will make full use of resources and provide Mevion with assistance in all aspects from project planning to customer support.

Proton therapy is an advanced form of radiation therapy that can reduce the risk of surrounding healthy tissues and critically sensitive organs being exposed to unnecessary radiation. Due to the development of small proton therapy systems, the use of proton therapy has rapidly expanded. Mevion is the first company to innovate this new method of proton therapy, providing the smallest system available today.

Dr. James Meng, President of Mevion Medical Systems, said: "We are honored to have a mature partner like Hermes Advanced Therapy Systems as our extended team in Taiwan and Southeast Asia. The proton therapy market in this region is growing, and our partnership with HATS will make the most Cancer patients who require proton therapy receive proton therapy.”

The MEVION S250i proton therapy system equipped with HYPERSCAN pen-tip scanning uses an adaptive multi-leaf collimator to sharpen the radiation beam, so that the dose to the tumor is more accurate and conformal than before, thereby improving the effectiveness of proton therapy. The advanced clinical capabilities and compact size of the system have changed the landscape of proton therapy.